Please login to the form below

Not currently logged in
Email:
Password:

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace
AstraZeneca, Marc Dunoyer

AstraZeneca (AZ) has announced that Marc Dunoyer will take over from Simon Lowth as the company's chief financial officer.

The decision ends a near four-month search for a replacement after Lowth announced in July his intention to leave the company for a similar role at natural gas firm BG Group.

Dunoyer only joined AZ in June this year as executive VP, global portfolio and product strategy, to support the company's global restructuring programme. He was previously head of the rare diseases business at big pharma rivals GlaxoSmithKline (GSK).

AZ's CEO Pascal Soriot said he was “delighted” with the appointment of Dunoyer.

“Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership,” said Soriot.

Dunoyer will begin his new role on November 1, reporting directly to Soriot.

AZ said his replacement as as executive VP, global portfolio and product strategy will be announced separately.

1st November 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ahair@onyxhealth.com

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...